Menu
Not yet recruiting NCT07658378

Continuous Infusion Versus Intermittent IV Bolus of Cefazolin: Prevention of Surgical Site Infection During CABG Surgeries in Egyptian Patients.

Phase IV Interventional Surgical Site Infection (SSI)

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Cefazolin 2 g Infusion, Cefazolin 2 GM Injection.
Who it may be relevant to
Registry conditions: Surgical Site Infection (SSI). Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Overview

A randomized controlled trial on adults who underwent coronary artery bypass grafting (CABG) surgery. To evaluate the effectiveness of intraoperative continuous infusion (CI) of cefazolin compared with intermittent (INT) cefazolin administration in preventing surgical site infection in the CABG population. Eligible patients will be randomized using a block design into 2 groups: intervention and control. The intervention group will use continuous infusion of cefazolin (CI), while the control group will follow the traditional presurgical prophylaxis protocol of intermittent cefazolin doses (INT).

Interventions

  • Drug Cefazolin 2 g Infusion
    To evaluate the effectiveness of intraoperative continuous infusion (CI) of cefazolin compared with intermittent (INT) cefazolin administration in preventing SSIs in a CABG (coronary artery bypass grafting) population.
  • Drug Cefazolin 2 GM Injection
    To evaluate the effectiveness of intermittent (INT) cefazolin administration in preventing SSIs in a CABG (coronary artery bypass grafting) population.

Primary outcome measures

  • Incidence of SSI [Time frame: Within 3 months after surgery]

Eligibility criteria

Inclusion criteria

  • Cardiothoracic ICU-admitted patients who underwent CABG on CPB.

Exclusion criteria

  • Patients who require reoperation within 30 days.
  • Immunosuppressant patients.
  • Patients who are not adherent to the protocol time or dosing, either preoperatively, during, or postoperatively.
  • Pregnancy or breastfeeding.
  • Patients who refused to sign the informed consent.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Single blind
Primary purpose
Prevention

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT07658378 · 08112025

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗